Jazz Pharmaceuticals Plc (JAZZ)

121.55
1.80 1.50
NASDAQ : Health Technology
Prev Close 119.77
Open 120.33
Day Low/High 120.00 / 122.17
52 Wk Low/High 113.52 / 165.66
Volume 111.68K
Avg Volume 479.80K
Exchange NASDAQ
Shares Outstanding 56.62M
Market Cap 6.68B
EPS 7.50
P/E Ratio 10.68
Div & Yield N.A. (N.A)
3M, Toll Brothers: Analysts' New Ratings

3M, Toll Brothers: Analysts' New Ratings

3M downgraded at BofA/Merrill from Neutral to Underperform. Toll Brothers upgraded at Goldman from Neutral to Buy.

Jazz Reaches New 52-Week High (JAZZ)

Jazz Reaches New 52-Week High (JAZZ)

Jazz Pharmaceuticals (Nasdaq:JAZZ) hit a new 52-week high Tuesday as it is currently trading at $35.18, above its previous 52-week high of $34.97 with 238,297 shares traded as of 10:16 a.m. ET. Average volume has been 778,200 shares over the past 30 days.

Equity Buyers Too Eager Today

This is a bearish sign after this week's big selloff because it signifies that sentiment hasn't shaken out enough bulls to turn the market higher.

Jazz Pharmaceuticals Inc. Stock Upgraded (JAZZ)

Jazz Pharmaceuticals Inc. Stock Upgraded (JAZZ)

Jazz Pharmaceuticals (Nasdaq:JAZZ) has been upgraded by TheStreet Ratings from a hold to buy.

Jazz Stock Hits New 52-Week High (JAZZ)

Jazz Stock Hits New 52-Week High (JAZZ)

Jazz Pharmaceuticals (Nasdaq:JAZZ) hit a new 52-week high Tuesday as it is currently trading at $34.63, above its previous 52-week high of $34.62 with 47,135 shares traded as of 10:11 a.m. ET. Average volume has been 790,800 shares over the past 30 days.

Jazz Stock Hits New 52-Week High (JAZZ)

Jazz Stock Hits New 52-Week High (JAZZ)

Jazz Pharmaceuticals (Nasdaq:JAZZ) hit a new 52-week high Wednesday as it changed hands at $33.95 compared with its previous 52-week high of $33.83. Jazz is currently trading at $32.96 with 164,751 shares changing hands as of 10:36 a.m.

Jazz Stock Hits New 52-Week High (JAZZ)

Jazz Stock Hits New 52-Week High (JAZZ)

Jazz Pharmaceuticals (Nasdaq:JAZZ) hit a new 52-week high Thursday as it changed hands at $30.15 compared with its previous 52-week high of $30.08. Jazz is currently trading at $30.05 with 265,810 shares changing hands as of 11:26 a.m.

5 Stocks Hitting Highs Even Amid Turmoil

5 Stocks Hitting Highs Even Amid Turmoil

Examworks and Polycom, among other unknown stocks, are still gaining as the equity market drops.

Jazz Stock Hits New 52-Week High (JAZZ)

Jazz Stock Hits New 52-Week High (JAZZ)

Jazz Pharmaceuticals (Nasdaq:JAZZ) hit a new 52-week high Wednesday as it changed hands at $29.78 compared with its previous 52-week high of $29.73. Jazz is currently trading at $29.62 with 295,816 shares changing hands as of 10:36 a.m.

3 Market-Leading Stocks Headed Even Higher

3 Market-Leading Stocks Headed Even Higher

These stocks are bucking recent market weakness and could be headed even higher.

Jazz Stock Hits New 52-Week High (JAZZ)

Jazz Stock Hits New 52-Week High (JAZZ)

Jazz Pharmaceuticals (Nasdaq:JAZZ) hit a new 52-week high Thursday as it changed hands at $26.35 compared with its previous 52-week high of $25.48. Jazz is currently trading at $26.02 with 255,673 shares changing hands as of 10:06 a.m..

Jazz Stock Hits New 52-Week High (JAZZ)

Jazz Stock Hits New 52-Week High (JAZZ)

Jazz Pharmaceuticals (Nasdaq:JAZZ) hit a new 52-week high Tuesday as it changed hands at $25.23 compared with its previous 52-week high of $23.75. Jazz is currently trading at $25.11 with 91,592 shares changing hands as of 9:31 a.m..

Biotech Winners & Losers: Geron, Jazz Pharma

Stem-cell outfit Geron falls and Jazz Pharmaceuticals continues to rebound Thursday in a quiet session for biotech.

Update: Perfect FDA Drug Approval Pickers

Update: Perfect FDA Drug Approval Pickers

Meet the five contestants with perfect 5-0 records so far in TheStreet's FDA Drug-Approval Contest

FDA O-Fer October Drug Approvals

U.S. regulators have issued four drug approval decisions this month and all have been rejections.

Jazz Pharm: FDA Rejects Fibromyalgia Drug

FDA asks for more information, including clinical trials, in refusing to approve Jazz's fibromyalgia drug JZP-6.

Biotech Sector Weekly Rewind

Biotech Sector Weekly Rewind

Adam Feuerstein's take on the biotech sector's hits and misses during the week ended Oct. 8, 2010.

Readers Pick Drug Approval Winners & Losers

FDA will approve drugs by Alkermes and Amylin but will turn away Arena and Vivus, according to reader predictions in TheStreet's FDA Drug-Approval Contest

Play TheStreet's FDA Drug-Approval Contest

Try to correctly predict the approval decisions made by the U.S. Food and Drug Administration on 11 new drugs in October.

Biotech Stock Mailbag: Jazz Pharma

Biotech columnist Adam Feuerstein answers readers' questions about drug and health care-related firms.

FDA Advisory Panels: A Coin Flip

FDA advisory panels in 2010 are voting against new drugs more than any other time since 2007.

7 Expert Stock Picks for September

InvestorPlace experts offer up their best trading ideas for this uncertain market.

3Par, Hewlett-Packard, Jazz Pharma Big Movers

3Par, Hewlett-Packard, Jazz Pharmaceuticals among companies making big market moves

Action Alerts, HP Vs. Dell, Stocks Under $10

Gregg Greenberg breaks down today's market action with guests Stephanie Link, director of research at TheStreet, David Peltier, TheStreet's Stocks Under $10 portfolio manager and James Rogers, TheStreet's senior technology writer.

Jazz Pharma - Live Coverage of FDA Review

Live coverage of FDA panel review of Jazz Pharma's fibromyalgia drug.

Jazz Pharma: FDA Panel Live Blog

Here's our live coverage of the FDA review of Jazz's fibromyalgia drug JZP-6.

Jazz Pharma: FDA Speaks Before Friday's Panel

FDA raises no issues with efficacy or safety of Jazz's fibromyalgia drug but is worried about potential for abuse and misuse.

Biotech Stock Mailbag - 2Q Updates

Biotech columnist Adam Feuerstein answers readers' questions about drug and health care-related firms.

Jazz Pharma - FDA Panel Prep

Here's what to expect from Jazz Pharma when an FDA panel reviews the company's fibromyalgia drug on Aug. 20.

Biotech Stock Mailbag: Seattle Genetics

Biotech columnist Adam Feuerstein answers readers' questions about drug and health care-related firms.

TheStreet Quant Rating: B- (Buy)